会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明授权
    • Optimizing therapy outcomes for peritoneal dialysis
    • 优化腹膜透析治疗效果
    • US09348975B2
    • 2016-05-24
    • US12431458
    • 2009-04-28
    • Ying-Cheng LoAlp AkonurIsaac Martis
    • Ying-Cheng LoAlp AkonurIsaac Martis
    • G06F19/00A61M1/28
    • G06F19/3481A61M1/28A61M1/281A61M1/282A61M2205/3569A61M2205/52A61M2205/6018A61M2205/6054A61M2205/6072G06F19/00
    • Peritoneal dialysis therapy outcomes have been calculated for a variety of dwell times of peritoneal dialysis fluids in the peritoneal cavities of dialysis patients using kinetic modeling. The length of dwell time should not be the same for every patient, but should vary according to the patient condition and needs. Some patients have a potential for expressing greater ultrafiltrate into the dialysis fluid, and these patients can benefit from a longer dwell time, whereas other patients with less potential will not benefit from a longer dwell time. An optimal or peak time is observed for each peritoneal dialysis therapy outcome, such as ultrafiltrate volume rate, urea clearance (Kt/V), and creatinine clearance, while minimizing hydrocarbon absorption. These values and input parameters can be used to tailor the peritoneal dialysis dwell time for each patient, estimating the peak dwell time that will yield the best therapy outcome for each patient.
    • 已经使用动力学模型计算了透析患者腹膜腔腹膜透析液的各种停留时间的腹膜透析治疗结果。 每个患者的停留时间长度不应相同,但应根据患者情况和需要而变化。 一些患者有可能在透析液中表达更多的超滤液,这些患者可以从更长的停留时间中受益,而潜在的潜力较小的患者不会受益于更长的停留时间。 对于每个腹膜透析治疗结果,观察到最佳或高峰时间,例如超滤液体积率,尿素清除率(Kt / V)和肌酐清除率,同时使烃吸收最小化。 这些值和输入参数可用于定制每个患者的腹膜透析停留时间,估计将为每位患者产生最佳治疗结果的峰值停留时间。